ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer

Reuters12-16 22:01

ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer

ImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin $(BCG)$ shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591803539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591803539","market":"us","top_or_hot":-1,"title":"ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin <a href=\"https://laohu8.com/S/BCG\">$(BCG)$</a> shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin <a href=\"https://laohu8.com/S/BCG\">$(BCG)$</a> shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6Qm9P:1","article_id":"2591803539","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591803539","pubTimestamp":1765893704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA  in combination with Bacillus Calmette-Guérin  shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer . The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio报告ANKTIVA加BCG治疗BCG无反应膀胱癌的三年生存率为96%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer\n    \n\nImmunityBio, Inc. announced new clinical study results demonstrating that treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin $(BCG)$ shows a 96% bladder cancer-specific survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, published in the January 2026 edition of The Journal of Urology, also indicate favorable outcomes in disease-free survival, progression-free survival, and high rates of cystectomy avoidance, with the median to cystectomy not yet reached. Safety data revealed a 3% incidence of grade 3 treatment-related adverse events, with no grade 4 or 5 events reported. ANKTIVA is currently approved in the U.S., U.K., and has conditional marketing authorization in the EU for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216185945) on December 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591803539","isCrawlerRequest":true}